Leukemia & Lymphoma

Papers
(The H4-Index of Leukemia & Lymphoma is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study79
Impact of SF3B1 mutation in myelofibrosis42
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma40
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia35
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant31
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia30
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review24
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis24
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination23
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state23
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents23
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia23
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma23
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity22
Correction22
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma21
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans21
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia20
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax20
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma20
0.064903020858765